MedTrace Logo

Immune-Inflammatory Markers in Aortic Dissection

NCT07683260 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 127

Last updated 2026-07-06

No results posted yet for this study

Summary

Identifying early on which patients with acute aortic dissection require closer monitoring may help with care planning. If simple, inexpensive values obtained from routine blood tests can provide additional information for assessing risk, this knowledge could in the future help physicians follow their patients more effectively. The aim of this study is to investigate this possibility scientifically.

It is based on the evaluation of information obtained from blood tests that are already being performed. Its purpose is to generate general knowledge that may contribute to the care of future patients. The study itself does not change decisions about your treatment; all decisions regarding your treatment and follow-up rest with your doctor, who evaluates your condition in its entirety.

It is designed to evaluate the relationship between preoperative/postoperative systemic immune-inflammatory and nutritional markers (SII, NLR, PLR, CAR, PNI) and indicators of mortality and morbidity (length of stay and changes in kidney function) in patients with acute aortic dissection. The goal is to investigate the potential of easily accessible laboratory parameters to contribute to risk stratification. The relationship between the markers and outcomes will be analyzed using appropriate statistical methods.

This study is based on the evaluation of information in patients' existing medical records and blood tests. The data are processed in accordance with the relevant ethical rules and privacy principles, with patient identity kept confidential. Taking part in the study does not require any additional procedure, additional blood draw, or change in treatment.

Conditions

  • Acute Aortic Dissection
  • Surgery (Cardiac)
  • Systemic Immune-inflammation Index
  • Postoperative Death
  • Neutrophil to Lymphocyte Ratio
  • CRP to Albumin Ratio
  • Prognostic Nutritional Index
  • Renal Failure Acute Chronic
  • Platelet to Lymphocyte Ratio

Sponsors & Collaborators

  • Bursa City Hospital

    lead OTHER_GOV

Principal Investigators

  • esat demirel, MD · Bursa City Hospital

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-18
Primary Completion
2026-06-20
Completion
2026-06-23

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07683260 on ClinicalTrials.gov